NYSE:FTV 4 February 2026

Fortive stock jumps on upbeat 2026 profit view after Q4 beat, buybacks

Fortive shares jumped 12.4% to $61.07 after the company forecast 2026 adjusted earnings of $2.90 to $3.00 per share, topping analyst estimates. Fourth-quarter adjusted EPS reached $0.90 on $1.12 billion in revenue, with automation segment sales up 5.3%. About 8.5 million shares traded by midafternoon. Management will present at Citi and Barclays industrial conferences later this month.

4 February 2026

Earnings·NYSE:FTV

Goldman Sachs Cuts Olema Pharmaceuticals Price Target to $27 Amid Mixed Analyst Ratings
March 18, 2026, 8:50 AM EDT. The Goldman Sachs Group lowered its price target for Olema Pharmaceuticals (NASDAQ:OLMA) from $38 to $27, signaling a cautious outlook despite maintaining a "buy" rating. This new target implies a potential 79% gain from the current $15 price. Other firms show varied opinions: JPMorgan raised their target to $32 with an "overweight" rating, Citigroup increased theirs to $62, and Guggenheim cut theirs to $38, both rating the stock "buy." Olema's shares dropped 9.3% to $15.06, heading away from a 52-week high of $36.26. The company, with a $1.03 billion market cap, reported a slight earnings beat last quarter but posted a negative price-to-earnings ratio of -8.10, reflecting ongoing losses. Insider sales totaling millions add to mixed signals on future stock performance.